United States of America
Dr. Mark Bogart is a highly successful biotech entrepreneur. He discovered and commercialized a key part of the maternal serum triple test for Down’s Syndrome carried out on pregnant women. The test became part of the standard of care for pregnant women in the first world. Dr. Bogart is an investor in over a dozen biomedical and technology companies and currently serves on the Boards of Genetic Information Management Systems, Kuehnle Agrosystems, and Hawaii Biotech, Inc. He is a partner in AppliSci Limited. Dr. Bogart received a BA from the University of California, San Diego (UCSD) and a PhD in a joint program between UCSD and San Diego State University. He did his post-doctoral training in Genetics at UCSD and is Board Certified in Clinical Cytogenetics by the American Board of Medical Genetics and was a founding member of the American College of Medical Genetics. During his academic career in clinical and research genetics Dr. Bogart published over 50 scientific articles and received three patents. Transitioning from academics to business he started a patent management and licensing company (Biomedical Patent Management Corp.) and a diagnostic genetics laboratory (Mid-Pacific Genetics) which was subsequently sold to the Queen’s Medical Center in Honolulu. He has served on a number of State committees and non-profit Boards in both California and Hawaii.
Clinical Toxicology Clinical and Laboratory Research